SECURITIES AND EXCHANGE COMMISSION

 

 

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

 

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event) September 8, 2014; (September 2, 2014)

 

GUIDED THERAPEUTICS, INC.

 (Exact Name of Registrant as Specified in Its Charter)

 

     
Delaware 0-22179 58-2029543
( State or Other Jurisdiction of (Commission File Number) (IRS Employer Identification No.)
Incorporation)    

 

 

   

5835 Peachtree Corners East, Suite D

Norcross, Georgia

(Address of Principal Executive Offices)

30092

(Zip Code)

 

Registrant's Telephone Number, Including Area Code:      (770) 242-8723

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 

 

  [ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
  [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
  [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
  [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     

 

  

1
 

   

Item 1.01. Entry into a Material Definitive Agreement.

 

Regulation S Offering

On September 2, 2014, the Company accepted a subscription agreement from ITEM Medikal Teknolojileri LTD STI, a Turkish corporation (“ ITEM ”), pursuant to which the Company will sell 651,042 shares of common stock and a warrant to purchase an additional 325,521 shares to ITEM, for an aggregate purchase price of $200,000 (the “ Regulation S Offering ”). The warrant will be immediately exercisable, have an exercise price per share of $0.4608, and expire five years from the date of issuance. The warrant will be subject to a mandatory exercise provision should the average trading price of our common stock over any 30 consecutive day trading period exceed $0.9216. Provided that ITEM continues to hold at least 50% of the shares purchased pursuant to the subscription agreement, if the Company offers more favorable terms for the purchase of its equity securities, on the whole, to other investors in any subsequent private placement (other than under certain specified circumstances), then ITEM will be eligible, subject to requirements of law, to participate in such subsequent transactions at the same terms as those offered to other investors in such private placement. In addition, should ITEM, at any time before December 31, 2015, purchase an aggregate of $2.0 million in shares of the Company’s equity securities, ITEM will be entitled to designate an individual to our board of directors, and the designee will be nominated by our board at subsequent annual meetings for as long as ITEM or its affiliates continue to hold at least 50% of the shares of our common stock held at December 31, 2015.

Pursuant to a registration rights agreement between ITEM and the Company to be entered into in connection with the Regulation S Offering, the Company will grant ITEM “piggy-back” registration rights with respect to the next registration statement the Company files on behalf of selling stockholders.

The proceeds from the Regulation S Offering will be used for efforts to achieve FDA approval for the Company’s LuViva non-invasive cervical cancer detection device, to increase manufacturing and international sales of LuViva, to enhance the Company’s intellectual property portfolio, and other related corporate purposes. The Regulation S Offering is expected to close during the week of September 8, 2014.

ITEM is the Company’s exclusive distributor of its LuViva advanced cervical cancer detection devise in the Middle East and North Africa.

The sale of securities to ITEM is being made to a non-U.S. person in an offshore offering in accordance with Regulation S under the Securities Act of 1933, as amended (the “ Securities Act ”).

The above description of the Regulation S Offering is qualified in its entirety by reference to the subscription agreement, the form of registration rights agreement, and the form of warrant to be issued to ITEM, attached as Exhibits 10.1, 4.1, and 10.2, respectively, to this current report and incorporated herein by reference.

On September 8, 2014, the Company issued a press release announcing the Regulation S Offering, a copy of which is attached as Exhibit 99.1 to this current report and is incorporated herein by reference.

This current report on Form 8-K is neither an offer to sell nor the solicitation of an offer to buy any securities. The securities have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act.

Item 3.02 Unregistered Sales of Equity Securities

 

The information set forth under Item 1.01 under the caption “Regulation S Offering” is incorporated by reference into this Item 3.02.

 

2
 

Item 9.01      Financial Statements and Exhibits.

(d) Exhibits.

   
Number Exhibit
   
4.1 Form of Warrant (Regulation S)
10.1 Subscription Agreement of ITEM, dated August 29, 2014, and acceptd by the Company on September 2, 2014
10.2 Form of Registration Rights Agreement
99.1 Press Release, dated September 8, 2014 (Regulation S Offering)

 

   

3
 

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

      GUIDED THERAPEUTICS, INC .  
       
    By:   /s/ Gene Cartwright  
      Gene Cartwright, Ph.D.  
      President and Chief Executive Officer  
  Date:  September 8, 2014      

 

  

4

Exhibit 4.1

THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT ARE SECURITIES THAT ARE BEING OFFERED AND SOLD PURSUANT TO REGULATION S UNDER THE SECURITIES ACT OF 1933 (THE “SECURITIES ACT”) IN AN “OFFSHORE TRANSACTION” TO PERSONS WHO ARE NOT “U.S. PERSONS” (EACH AS DEFINED IN REGULATION S UNDER THE SECURITIES ACT). ACCORDINGLY, NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN OR WILL BE REGISTERED UNDER THE SECURITIES ACT, OR ANY APPLICABLE U.S. STATE OR FOREIGN SECURITIES LAWS, AND, UNLESS SO REGISTERED, MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OR, DIRECTLY OR INDIRECTLY, TO U.S. PERSONS EXCEPT IN COMPLIANCE WITH THE PROVISIONS OF REGULATION S UNDER THE SECURITIES ACT, PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN EACH CASE ONLY IN COMPLIANCE WITH APPLICABLE STATE AND FOREIGN SECURITIES LAWS. IN ADDITION, HEDGING TRANSACTIONS INVOLVING THESE SECURITIES MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE SECURITIES ACT.

Guided Therapeutics, INC.

Form of Common Stock Purchase Warrant
(Regulation S)

  Warrant Terms  
  Warrant No.   Warrant Shares   Exercise Price  
      325,521   $0.4608 per share  
  Date of Issuance       Termination Date  
             

 

This Common Stock Purchase Warrant (this “ Warrant ”) certifies that, for value received, ITEM MEDIKAL TEKNOLOJILERI LTD STI or its assigns (the “ Holder ”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Date of Issuance listed on the table above (the “ Initial Exercise Date ”) and on or prior to the close of business on the Termination Date listed on the table above (the “ Termination Date ”) but not thereafter, to subscribe for and purchase from GUIDED THERAPEUTICS, INC., a Delaware corporation (the “ Company ”), up to that number of shares of the Company’s common stock, par value $.001 per share (the “ Common Stock ”), listed in the table above (the “ Warrant Shares ”).

1.        Definitions . Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Subscription Agreement of the Holder (the “ Subscription Agreement ”), dated August 29, 2014, and accepted by the Company on September 2, 2014.

2.        Exercise .

(a)      Exercise of Warrant . Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company (or such other office or agency of the Company as it may designate by notice in writing to the registered Holder at the address of the Holder appearing on the books of the Company) of a duly executed facsimile copy of the attached Notice of Exercise Form (the date such Notice of Exercise is received by the Company, the “ Warrant Exercise Date ”); and, within three days of trading on the principal market or exchange on which the Common Stock trades (such market, the “ Trading Market ” and each such day, a “ Trading Day ”) of the Warrant Exercise Date, receipt of payment by the Company of the aggregate Exercise Price of the shares thereby purchased by wire transfer or cashier’s check drawn on a United States bank. Notwithstanding anything herein to the contrary, the Holder will not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and this Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancelation within three Trading Days of the date the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.

(b)      Exercise Price . The purchase price of one share of Common Stock under this Warrant shall be equal to the exercise price listed in the table above, subject to adjustment as provided in this Warrant (the “ Exercise Price ”).

(c)      Mechanics of Exercise .

(i)        Delivery of Warrant Shares Upon Exercise . The Company shall cause its transfer agent to transmit the Warrant Shares purchased hereunder to the Holder by physical delivery to the address specified by the Holder in the Notice of Exercise, by the date that is three Trading Days after the Warrant Exercise Date (such date, the “ Warrant Share Delivery Date ”), provided that the Holder has paid any required Exercise Price for the portion of this Warrant being exercised on or prior to such Warrant Share Delivery Date. This Warrant will be deemed to have been exercised on the Warrant Exercise Date. The Warrant Shares will be deemed to have been issued, and Holder or any other person so designated to be named therein shall be deemed to have become a holder of record of such shares for all purposes, as of the Warrant Exercise Date, once Holder has paid to the Company the Exercise Price and paid all taxes required to be paid by the Holder, if any, pursuant to Section 2(c)(v) prior to the issuance of such shares.

(ii)      Delivery of New Warrants Upon Exercise . If this Warrant is exercised in part, the Company shall, at the request of the Holder and upon surrender of this Warrant, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant will in all other respects be identical with this Warrant.

(iii)     Rescission Rights . If the Company fails to cause its transfer agent to transmit to the Holder the Warrant Shares pursuant to Section 2(c)(i) by the Warrant Share Delivery Date, then, the Holder will have the right to rescind such exercise.

(iv)    No Fractional Shares or Scrip . The Company shall not issue fractional shares or scrip representing fractional shares upon the exercise of this Warrant. As to any fraction of a share that the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.

(v)      Charges, Taxes and Expenses . The Company shall not charge the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or, if permitted by applicable law, in such name or names as may be directed by the Holder. If Warrant Shares are to be issued in a name other than the name of the Holder, then this Warrant when surrendered for exercise must be accompanied by the attached Assignment Form duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental to such assignment.

(vi)    Closing of Books . The Company will not close its stockholder books or records in any manner that prevents the timely exercise of this Warrant pursuant to its terms.

(d)      Call Provision . Subject to the provisions of this Section 2(d), if, at any time after the Initial Exercise Date , (i) the VWAP (as defined below) for each of 30 consecutive Trading Days (the “ Measurement Period ”) exceeds $0.9216 per share, and (ii) the Holder is not in possession of any information that constitutes, or might constitute, material non-public information that was provided by the Company, then the Company may, within three Trading Days after the end of such Measurement Period, call for cancelation of all or any portion of this Warrant for which a Notice of Exercise has not yet been delivered (such right, a “ Call ”) for consideration equal to $.001 per Warrant Share. To exercise this right, the Company must deliver to the Holder an irrevocable written notice (a “ Call Notice ”), indicating the portion of unexercised portion of this Warrant to which the notice applies. If the conditions set forth below for such Call are satisfied from the period from the date of the Call Notice through and including the Call Date (as defined below), then any portion of this Warrant subject to such Call Notice for which the Company does not receive a Notice of Exercise by the Call Date will be canceled at 6:30 p.m. (New York City time) on the tenth Trading Day after the date the Call Notice is received by the Holder (such date and time, the “ Call Date ”). Any unexercised portion of this Warrant to which the Call Notice does not pertain will be unaffected by such Call Notice. In furtherance thereof, the Company shall honor all Notices of Exercise with respect to Warrant Shares subject to a Call Notice that are tendered through 6:30 p.m. (New York City time) on the Call Date. Any Notice of Exercise delivered following a Call Notice that calls less than all the Warrants will first reduce to zero the number of Warrant Shares subject to such Call Notice prior to reducing the remaining Warrant Shares available for purchase under this Warrant. For example, if (A) this Warrant then permits the Holder to acquire 100 Warrant Shares, (B) a Call Notice pertains to 75 Warrant Shares, and (C) prior to 6:30 p.m. (New York City time) on the Call Date the Holder tenders a Notice of Exercise in respect of 40 Warrant Shares, then (x) on the Call Date the right under this Warrant to acquire 35 Warrant Shares will be automatically canceled, (y) the Company, in the time and manner required under this Warrant, will have issued and delivered to the Holder 40 Warrant Shares in respect of the exercises following receipt of the Call Notice, and (z) the Holder may, until the Termination Date, exercise this Warrant for 25 Warrant Shares (subject to adjustment as provided in this Warrant and subject to subsequent Call Notices). Subject again to the provisions of this Section 2(d), the Company may deliver subsequent Call Notices for any portion of this Warrant for which the Holder has not delivered a Notice of Exercise. Notwithstanding anything to the contrary set forth in this Warrant, the Company may not deliver a Call Notice or require the cancelation of this Warrant (and any such Call Notice shall be void), unless, from the beginning of the Measurement Period through the Call Date, (1) the Company shall have honored in accordance with the terms of this Warrant all Notices of Exercise delivered by 6:30 p.m. (New York City time) on the Call Date, and (2) there is a sufficient number of authorized shares of Common Stock for issuance of all Securities under the Transaction Documents. For purposes of this Section 2(d), “ VWAP ” means, for the Common Stock as of any date, the dollar volume-weighted average price for such security on the Trading Market during the period beginning at 9:30:01 a.m., New York time, and ending at 4:00:00 p.m., New York time, as reported by Bloomberg through its “Volume at Price” function or, if the foregoing does not apply, the dollar volume-weighted average price of such security in the over-the-counter market on the electronic bulletin board for such security during the period beginning at 9:30:01 a.m., New York time, and ending at 4:00:00 p.m., New York time, as reported by Bloomberg, or, if no dollar volume-weighted average price is reported for such security by Bloomberg for such hours, the average of the highest closing bid price and the lowest closing ask price of any of the market makers for such security as reported by OTC Markets Group Inc. If VWAP cannot be calculated for such security on such date on any of the foregoing bases, the VWAP of such security on such date will be the fair market value as mutually determined by the Company and the Holder. All such determinations will be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during such period.

3.        Certain Adjustments .

(a)      Stock Dividends and Splits . If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, will not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price will be adjusted to an amount equal to the Exercise Price immediately before such event multiplied by a fraction, the numerator of which will be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and the denominator of which will be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant will be proportionately adjusted such that the aggregate Exercise Price of this Warrant will remain unchanged. Any adjustment made pursuant to this Section 3(a) will become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and will become effective immediately after the effective date in the case of a subdivision, combination or re-classification.

(b)      Calculations . All calculations under this Section 3 will be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date will be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

(c)      Notice to Holder . Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly mail to the Holder a notice setting forth the Exercise Price after such adjustment and setting forth a brief statement of the facts requiring such adjustment.

4.        Transfer of Warrant .

(a)      Transferability . Subject to compliance with applicable securities laws (as determined in good faith by the Company), the Holder may transfer this Warrant and all rights hereunder, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be canceled. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.

(b)      New Warrants . This Warrant may be divided or combined with other Warrants upon presentation hereof at the principal office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges will be dated the Initial Exercise Date set forth on the first page of this Warrant and will be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

(c)      Warrant Register . The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “ Warrant Register ”), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

5.        Miscellaneous .

(a)      No Rights as Stockholder Until Exercise . This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(c)(i), except as expressly set forth in Section 3.

(b)      Loss, Theft, Destruction or Mutilation of Warrant . Upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it, and upon surrender and cancelation of such Warrant or stock certificate, if mutilated, the Company shall make and deliver a new Warrant or stock certificate of like tenor, in lieu of such Warrant or stock certificate.

(c)      Saturdays, Sundays, Holidays, etc . If the last or appointed day for the taking of any action or the expiration of any right required or granted herein is not a U.S. business day, then such action may be taken or such right may be exercised on the next succeeding U.S. business day.

(d)      Authorized Shares . During the period the Warrant is outstanding, the Company shall reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company’s issuance of this Warrant will constitute full authority to the Company’s officers, who are charged with the duty of executing stock certificates to execute and issue the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company shall take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. All Warrant Shares that may be issued upon the exercise of this Warrant will, upon such exercise and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).

Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but shall at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of the Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company shall (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be necessary to enable the Company to perform its obligations under this Warrant.

Before taking any action that would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.

(e)      Jurisdiction . All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of the Subscription Agreement.

(f)       Holder Representations, Warranties, Acknowledgements and Agreements . Upon any exercise or transfer of this Warrant (in whole or part), the Holder shall confirm the accuracy in all respects of the representations and warranties set forth in Paragraph 1 of the Subscription Agreement as of the date of such exercise or transfer, and shall reaffirm the acknowledgements and agreements set forth in Paragraph 1 of the Subscription Agreement as of such date.

(g)      Nonwaiver and Expenses . No course of dealing or any delay or failure to exercise any right hereunder on the part of a party will operate as a waiver of such right or otherwise prejudice the party’s rights, powers or remedies. Without limiting any other provision of this Warrant or the Subscription Agreement, if a party willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the other party, the offending party shall pay to the offended party such amounts as are sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, incurred by the offended party in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.

(h)      Notices . Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company must be delivered in accordance with the notice provisions of the Subscription Agreement.

(i)        Limitation of Liability . No provision hereof, in the absence of any affirmative action by Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of Holder, shall give rise to any liability of Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.

(j)       Remedies . The parties, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The parties acknowledge that monetary damages would not be adequate compensation for any loss incurred by reason of a

breach by it of the provisions of this Warrant and hereby agree to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.

(k)      Successors and Assigns . Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby will inure to the benefit of and be binding upon the successors and permitted assigns of the parties. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and will be enforceable by the Holder or holder of Warrant Shares.

(l)        Amendment . This Warrant may not be amended or modified, and no provision may be waived, without the prior written consent of the Company and the Holder.

(m)    Severability . Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.

(n)      Headings . The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.

[Signature Page Follows]

 
 

This Warrant is being signed as of the date first stated above.

GUIDED THERAPEUTICS, INC.

 

By:_________________________________________

Name: Gene S. Cartwright

Title: President and Chief Executive Officer

 

 
 

NOTICE OF EXERCISE

[All capitalized terms have the meanings ascribed to such terms in
the Warrant to which this Notice of Exercise relates.]

 

TO: GUIDED THERAPEUTICS, INC.

 

(1)   The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any, in lawful money of the United States.

 

(2)   Please issue said Warrant Shares in the name of the undersigned.

 

The Warrant Shares shall be delivered by physical delivery of a certificate to:

 

_______________________________

 

_______________________________

 

_______________________________

 

The undersigned hereby confirms, as of the date hereof, that each of the representations and warranties set forth in Paragraph 1 of the Subscription Agreement is true and correct in all respects, and reaffirms all acknowledgements and agreements set forth in Paragraph 1 of the Subscription Agreement.

 

 

[SIGNATURE OF HOLDER]

 

Name of Entity:

 

_____________________________________________

 

 

 

By: _________________________________________________

 

Name of Authorized Signatory: ____________________________

 

Title of Authorized Signatory: ____________________________

 

 

Date: ______________

 

 

 
 

ASSIGNMENT FORM

 

[All capitalized terms have the meanings ascribed to such terms in
the Warrant to which this Notice of Exercise relates.]

 

(To assign the foregoing warrant, execute

this form and supply required information.

Do not use this form to exercise the warrant.)

 

FOR VALUE RECEIVED, [____] all of or [_______] shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned to

 

 

_______________________________________________ whose address is

 

_______________________________________________________________.

 

 

 

The undersigned hereby confirms, as of the date hereof, that each of the representations and warranties set forth in Paragraph 1 of the Subscription Agreement is true and correct in all respects, and reaffirms all acknowledgements and agreements set forth in Paragraph 1 of the Subscription Agreement.

 

 

[SIGNATURE OF HOLDER]

 

Name of Entity:

 

_____________________________________________

 

 

 

By: _________________________________________________

 

Name of Authorized Signatory: ____________________________

 

Title of Authorized Signatory: ____________________________

 

Date: ______________, _______

 

Exhibit 10.1

 

THIS SUBSCRIPTION AGREEMENT RELATES TO SECURITIES THAT ARE BEING OFFERED AND SOLD PURSUANT TO REGULATION S UNDER THE SECURITIES ACT OF 1933 (THE “SECURITIES ACT”) IN AN “OFFSHORE TRANSACTION” TO PERSONS WHO ARE NOT “U.S. PERSONS” (EACH AS DEFINED IN REGULATION S UNDER THE SECURITIES ACT). ACCORDINGLY, NONE OF THE SECURITIES TO WHICH THIS SUBSCRIPTION AGREEMENT RELATES HAVE BEEN OR WILL BE REGISTERED UNDER THE SECURITIES ACT, OR ANY APPLICABLE U.S. STATE OR FOREIGN SECURITIES LAWS, AND, UNLESS SO REGISTERED, NONE MAY BE OFFERED OR SOLD IN THE UNITED STATES OR, DIRECTLY OR INDIRECTLY, TO U.S. PERSONS EXCEPT IN COMPLIANCE WITH THE PROVISIONS OF REGULATION S UNDER THE SECURITIES ACT, PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN EACH CASE ONLY IN COMPLIANCE WITH APPLICABLE STATE AND FOREIGN SECURITIES LAWS. IN ADDITION, HEDGING TRANSACTIONS INVOLVING THE SECURITIES MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE SECURITIES ACT.

rEGULATION s SUBSCRIPTION AGREEMENT

To Guided Therapeutics, Inc., a corporation organized and incorporated under the laws of the State of Delaware (the “ Company ”):

The undersigned (“ Purchaser ”) irrevocably and unconditionally subscribes for 651,042 shares (the “ Subscription Shares ”) of the Company’s common stock, par value $.001 per share (the “ Common Stock ”), for a per share consideration of $0.3072 , and an aggregate consideration of $200,000  (the “ Aggregate Consideration ”), to be issued at the initial closing of the offering (the “ Offering ”) described in the term sheet attached as Exhibit A (the “ Term Sheet ”). The initial closing of the Offering (the “ Closing ”) will occur on a date selected by the Company, no later than four days after the Acceptance Date (as defined in Section 4).

In addition, as described in the Term Sheet, the Company shall issue Purchaser a warrant (the “ Warrant ”), in the form previously provided to Purchaser by the Company, to purchase 325,521 shares of Common Stock (the “ Warrant Shares ” and, with the Subscription Shares and the Warrant, the “ Securities ”) at an exercise price per share equal to $0.4608 .

The Purchaser’s legal name and contact information is as follows:

  Purchaser Name: ITEM Medikal Teknolojileri LTD STI  
  Address: Kizilirmak MAH Ufuk Univertesi  
    CAD No 8 D34  
  E-mail: zyazici@item.com.tr  
  Phone: +90 312 205 52 00  
  Fax: +90 312 205 52 40  

 

1.                   Purchaser represents, warrants, acknowledges and agrees as follows, as of the date of this Subscription Agreement and as of the Closing:

(a)                 Purchaser is duly organized under the laws of its jurisdiction of organization, and has obtained all necessary approvals to authorize execution and performance of this Subscription Agreement. The execution and delivery of this Subscription Agreement and the consummation of the transactions contemplated hereby will not result in the violation of applicable law, Purchaser’s constituent documents, or any agreement to which Purchaser is a party or is bound. Purchaser has duly executed and delivered this Subscription Agreement and it constitutes the valid and binding obligation of Purchaser, enforceable against Purchaser.

(b)                None of the Securities has been registered under the Securities Act of 1933, as amended (the “ Securities Act ”) or under any U.S. state securities or “blue sky” laws or the laws of any foreign jurisdiction, and the Company shall cause legends on each certificate or other document representing the Securities to the effect that such Securities have not been so registered and therefore are subject to restrictions on transfer. The Company is selling the Securities only in “offshore transactions” to persons other than “U.S. persons” and without any “directed selling efforts” in the United States (each as defined in Regulation S under the Securities Act (“ Regulation S ”)). Neither the Securities and Exchange Commission (the “ SEC ”) nor any other securities commission or similar regulatory authority has reviewed or passed on the merits of any of the Securities, nor have they reviewed any documents in connection with this Offering. There is no government or other insurance covering any of the Securities.

(c)                 Purchaser is acquiring the Securities for investment for Purchaser’s own account, not as a nominee or agent for any other person, and not with a view to the resale or distribution of any part thereof within the meaning of the Securities Act, and Purchaser has no present intention of selling, granting any participation in, or otherwise distributing the same. Purchaser has not and will not engage in any directed selling efforts in the United States, except that Purchaser may sell or otherwise dispose of any of the Securities pursuant to an effective registration statement or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Purchaser has not been formed for the specific purpose of acquiring the Securities. Purchaser does not have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participations to such person or to any third person, with respect to the Securities.

(d)                Purchaser is an “accredited investor” within the meaning of Rule 501(a) of Regulation D under the Securities Act.

(e)                 Purchaser has had the opportunity to review this Subscription Agreement, the Term Sheet, the form of the Warrant, filings by the Company with the SEC (including the Company’s annual report on Form 10-K for the year ended December 31, 2013 and subsequent periodic reports), and all documents and information that Purchaser has reasonably requested concerning its investment and the Company. Purchaser has had the opportunity to ask questions of the Company’s management regarding the Company’s business, management and financial affairs, and the terms of the Offering, which questions were answered to Purchaser’s satisfaction.

(f)                 The purchase of the Securities involves substantial risk. Purchaser can bear the economic risk of its investment and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of an investment in the Securities.

(g)                Purchaser has, independently and without reliance upon the Company or any other person, and based on such information as Purchaser has deemed appropriate, made its own investment analysis and decision to enter into this Subscription Agreement.

(h)                Purchaser has been advised to consult its own legal, tax and other advisors with respect to the merits and risks of an investment in the Securities and with respect to applicable resale restrictions, and Purchaser is solely responsible (and the Company is not in any way responsible) for compliance with (i) any applicable laws of the jurisdiction of Purchaser’s residence, and (ii) applicable resale restrictions.

(i)                  Purchaser is knowledgeable of, or has been independently advised as to, the applicable securities laws of the jurisdiction of its residence and is permitted to acquire the Securities under such securities laws or exemptions thereto, or otherwise without violation of such securities laws; such securities laws do not and will not require the Company to make, in the jurisdiction of Purchaser’s residence, any filings or seek any approvals, or prepare and file a prospectus or similar document or report, of any kind whatsoever, or undertake any continuous disclosure obligation. Purchaser will, at the request of the Company, deliver to the Company a certificate or opinion of local counsel from the jurisdiction of the Purchaser’s residence that will confirm the matters referred to in the paragraph to the reasonable satisfaction of the Company.

(j)                  Purchaser waives, to the fullest extent permitted by law, any rights of withdrawal, rescission or compensation for damages to which Purchaser might be entitled in connection with the distribution of the Securities (except for rights for compensation for damages expressly provided for in this Subscription Agreement).

(k)                Purchaser is not a U.S. person and is not acquiring the securities for the account or benefit of any U.S. person. Purchaser was outside the United States when receiving and executing this Subscription Agreement.

(l)                  The Securities will be characterized as “restricted securities” under Rule 144 of the Securities Act. Purchaser shall make all subsequent offers and sales of the Securities (i) in accordance with Rule 903 or Rule 904 of Regulation S, (ii) pursuant to registration of the Securities under the Securities Act, or (iii) pursuant to an available exemption from the registration requirements under the Securities Act. The Company will refuse to register any transfer of any of the Securities not made in accordance with this paragraph.

(m)              Purchaser shall not engage in any hedging transaction, including, without limitation, any short sale, with regard to the Securities unless in compliance with the Securities Act.

(n)                If Purchaser is affiliated with a non-U.S. banking institution (a “ Foreign Bank ”), or if Purchaser receives deposits from, makes payments on behalf of, or handles other financial transactions related to a Foreign Bank, then the Foreign Bank: (1) has a fixed address, other than solely an electronic address, in a country in which the Foreign Bank is authorized to conduct banking activities; (2) maintains operating records related to its banking activities; (3) is subject to inspection by the banking authority that licensed the Foreign Bank to conduct banking activities; and (4) does not provide banking services to any other Foreign Bank that does not have a physical presence in any country and that is not a regulated affiliate.

(o)                Neither Purchaser nor, to its knowledge, any person or entity controlling, controlled by or under common control with Purchaser, nor any person having a beneficial interest in Purchaser, nor any person on whose behalf Purchaser is acting: (i) is a person listed in the Annex to Executive Order No. 13224 (2001) issued by the President of the United States ( Executive Order Blocking Property and Prohibiting Transactions with Persons Who Commit, Threaten to Commit, or Support Terrorism ); (ii) is named on the List of Specially Designated Nationals and Blocked Persons maintained by the U.S. Office of Foreign Assets Control; (iii) is a non-U.S. shell bank or is providing banking services indirectly to a non-U.S. shell bank; (iv) is a senior non-U.S. political figure [1] or an immediate family member [2] or close associate [3] of such figure; or (v) is otherwise prohibited from investing in the Company pursuant to applicable U.S. anti-money laundering, anti-terrorist and asset control laws, regulations, rules or orders (categories (i) through (v), each a “ Prohibited Subscriber ”). Purchaser shall provide the Company, promptly upon request, all information that the Company reasonably deems necessary or appropriate to comply with applicable U.S. anti-money laundering, anti-terrorist and asset control laws, regulations, rules and orders. Purchaser consents to the disclosure to U.S. regulators and law enforcement authorities by the Company and its affiliates and agents of such information about Purchaser as the Company reasonably deems necessary or appropriate to comply with applicable U.S. anti-money laundering, anti-terrorist and asset control laws, regulations, rules and orders. To the extent Purchaser is a financial institution subject to the USA Patriot Act, Purchaser has met all of its obligations under such act. If, following Purchaser’s investment in the Company, the Company reasonably believes that Purchaser is a Prohibited Subscriber or is otherwise engaged in suspicious activity or refuses to promptly provide information that the Company requests, the Company has the right or may be obligated to prohibit additional investments, segregate the assets constituting the investment in accordance with applicable regulations or immediately require Purchaser to transfer the Securities. The Subscriber will have no claim against the Company or any of its affiliates or agents for any form of damages as a result of any of the foregoing actions.

(p)                The Company must approve in advance in writing any public disclosure of the Offering.

(q)                The Company will rely on the representations, warranties, acknowledgements, and agreements made by Purchaser in this Section 1.

2.                   By accepting this Subscription Agreement and the subscription made hereunder, the Company agrees as follows:

(a)                 Neither the Company nor anyone acting on its behalf shall offer, sell or solicit offers to buy or otherwise negotiate in respect of any security (as defined in the Securities Act) in a manner that would cause the offer and sale of the Subscription Shares and the Warrant to Purchaser to fail to be entitled to the exemption afforded by Regulation S under the Securities Act.

(b)                The Company shall use the proceeds from the issuance and sale of the Securities (and the exercise of the Warrant) for the purposes set forth in the Term Sheet.

(c)                 The Company shall continue to reserve from its authorized but unissued shares of Common Stock a sufficient number of shares of Common Stock to permit exercise of the Warrant.

(d)                With a view to making available to Purchaser the benefits of certain rules and regulations of the SEC that may permit the sale of the Shares, the Warrant and the shares of Common Stock issuable upon exercise of the Warrant to the public without registration, the Company shall use its commercially reasonable efforts to:

(i)                  make and keep public information available, as those terms are understood and defined in Rule 144 or any similar or analogous rule promulgated under the Securities Act, at all times after the Closing;

(ii)                file with the SEC, in a timely manner, all reports and other documents required of the Company under the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”);

(iii)              for no less than two years following the Closing, not terminate the Company’s status as an issuer required to file reports under the Exchange Act, even if the Exchange Act or the rules and regulations promulgated thereunder would permit such termination (except that the foregoing obligation will terminate in the event of an acquisition of the Company or substantially all of its assets); and

(iv)              so long as Purchaser owns any such securities, act cooperatively and expeditiously with Purchaser to remove or cause the removal of any restrictive legend on its Securities at the request of Purchaser at such time or after such time as such restrictions may legally be removed.

(e)                 The Company shall indemnify and hold harmless Purchaser and its affiliates, officers, directors, partners, members and employees, as applicable (each, an “ Indemnified Party ”), from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in permitted settlements, court costs and reasonable attorneys’ fees of one counsel and reasonable costs of investigation that any such Indemnified Party actually suffers or incurs as a result of (i) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Subscription Agreement or the Company’s Certificate provided for in Section 3(a) below, or (ii) any action instituted against an Indemnified Party in any capacity, by any stockholder of the Company who is not an Indemnified Party or an affiliate of an Indemnified Party, with respect to any of the transactions contemplated by this Subscription Agreement. Notwithstanding the foregoing, the Company will not be liable to any Indemnified Party under this Subscription Agreement to the extent that a loss, claim, damage or liability is attributable to Purchaser’s breach of any of the representations, warranties, covenants or agreements made by Purchaser in this Subscription Agreement, and in no event will the Company be required to indemnify and hold harmless any Indemnified Parties for any losses pursuant to this Section 2(e) in a cumulative aggregate amount exceeding the Aggregate Consideration unless it is determined by a court of competent jurisdiction that such losses resulted from the fraud or bad faith of the Company.

(f)                 The Company shall refuse to register any transfer of any of the Securities not made in accordance with paragraph 1(k).

(g)                If, any time after the Closing and on or before December 31, 2015 and provided that Purchaser continues to hold at least 50% of the Subscription Shares held at the Closing, the Company provides more favorable terms for the purchase of Common Stock (and warrants to purchase Common Stock), on the whole, to other investors in any subsequent offshore transactions constituting the Offering or any other private placement by the Company of equity securities (including, but not limited to, preferred equity securities) other than Excluded Securities (as defined below), then Purchaser will be eligible, subject to requirements of law, to participate in such transactions at the same terms as those offered to other investors in the Offering. “ Excluded Securities ” means securities issued (i) pursuant to an equity incentive plan of the Company, (ii) upon conversion or exercise of securities of the Company issued prior to the Closing Date, (iii) in connection with a merger, acquisition, consolidation or purchase of substantially all of the securities or assets of another entity, (iv) in connection with a strategic license agreement or other partnering arrangement not for the primary purpose of raising capital.

3.                   Purchaser’s obligations under this Subscription Agreement are subject to the following conditions:

(a)                 The Company shall have delivered to Purchaser a duly executed certificate, in substantially the form set forth as Exhibit B (the “ Company’s Certificate ”), and the representations and warranties set forth on the Company’s Certificate will be true and correct as of the Closing.

(b)                The Company shall have delivered to Purchaser a duly executed Registration Rights Agreement, in substantially the form set forth as Exhibit C (the “ Registration Rights Agreement ”).

(c)                 The Company shall have performed or complied with in all material respects all covenants contained in this Subscription Agreement to be performed by the Company on or prior to the Closing.

(d)                Against payment therefor by Purchaser and Purchaser’s compliance with each of its obligations under this Subscription Agreement, and delivery to the Company of a duly executed Registration Rights Agreement, the Company shall have delivered the Shares and the Warrant.

4.                   Purchaser’s obligations under this Subscription Agreement to acquire the Subscription Shares and the Warrant will expire on September 30, 2014, unless this Subscription Agreement is accepted by the Company prior to that time. The date on which the Company accepts this Subscription Agreement, and the subscription made hereunder, as evidenced by the Company’s signature below, is referred to as the “ Acceptance Date.

5.                   Purchaser understands and acknowledges that the subscription provided for herein is contingent upon the Company’s acceptance of this Subscription Agreement and the Closing in all material respects in accordance with the Term Sheet. Each party shall use its best efforts to do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry out the intent and accomplish the purposes of this Subscription Agreement and the consummation of the transactions contemplated hereby.

6.                   This Subscription Agreement is governed by, and is to be construed in accordance with, the laws of the State of New York, without giving effect to principles of conflicts of law.

7.                   This Subscription Agreement is binding upon the parties and their permitted successors and assigns and may be amended or terminated only by a writing signed by the parties.

8.                   Subject to the applicable statute of limitations, the representations, warranties and covenants contained in this Subscription Agreement and in the Company’s Certificate will survive the Closing and the delivery of the Securities.

9.                   Neither party may assign any of its rights or delegate any of its obligations under this Subscription Agreement without the prior written consent of the other party and any such purported assignment will be null and void. Nothing in this Subscription Agreement will be construed to give any third party any legal or equitable right, remedy or claim under or with respect to this Subscription Agreement, except such rights as will inure to a permitted assignee pursuant to this Section 9.

10.               This Subscription Agreement may be signed in any number of counterparts, all of which will be considered to be one and the same agreement.

[signature page follows]

 

 
 

 

Executed this 29 day of August, 2014.

Yours very truly,

 

 

ITEM MEDIKAL TEKNOLOJILERI LTD STI

 

 

By: /s/ Muzaffer Yazici

Name: Muzaffer Yazici

Title: Managing Director

ACCEPTED:

 

GUIDED THERAPEUTICS, INC.

 

 

By:  /s/ Gene S. Cartwright

Name: Gene S. Cartwright

Title: Chief Executive Officer

 

DATE: September 2, 2014

 


[1] A “senior non-U.S. political figure” is defined as a senior official in the executive, legislative, administrative, military or judicial branches of a foreign government (whether elected or not), a senior official of a major foreign political party, or a senior executive of a foreign government-owned corporation. In addition, a “senior foreign political figure” includes any corporation, business or other entity that has been formed by, or for the benefit of, a senior foreign political figure.

[2] “Immediate family” of a senior foreign political figure typically includes the figure’s parents, siblings, spouse, children and in-laws.

[3] A “close associate” of a senior foreign political figure is a person who is widely and publicly known to maintain an unusually close relationship with the senior foreign political figure, and includes a person who is in a position to conduct substantial domestic and international financial transactions on behalf of the senior foreign political figure.

Exhibit 10.2

Form of Registration Rights AGREEMENT

This Registration Rights Agreement (this “ Agreement ”) is dated as of ___________, 2014 and is by and between ITEM MEDIKAL TEKNOLOJILERI LTD STI, and GUIDED THERAPEUTICS, INC. (the “ Company ”).

As an inducement to the other parties hereto to make an investment in the Company’s securities pursuant to the subscription agreement, dated August 29, 2014 and accepted by the Company on September 2, 2014 (the “ Subscription Agreement ”), or pursuant to substantially similar subscription agreements, the Company has agreed to grant the other parties hereto certain rights set forth in this Agreement. All capitalized terms not otherwise defined herein have the meanings ascribed to them in the Subscription Agreement.

The parties therefore agree as follows:

SECTION 1.     Registration Rights.

1.1               Definitions . For purposes of this Agreement:

Holder ” means any (i) person who owns Registrable Securities at the relevant time and is a party to this Agreement or (ii) any permitted assignee of such person.

Registrable Securities ” means, as of any date of determination, (a) the Subscription Shares, (b) the Warrant Shares then issuable upon exercise in full of the Warrants, and (c) any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect to the foregoing; provided , however , that any such Registrable Securities will cease to be Registrable Securities for so long as (x) a Registration Statement with respect to the sale of such Registrable Securities is declared effective by the SEC under the 1933 Act and such Registrable Securities have been disposed of in accordance with such effective Registration Statement, or (y) such Registrable Securities have been previously sold in accordance with Rule 144.

1.2               Piggy-Back Registration . If the Company, at any time prior to a Holder’s disposition of more than 50% of the Registrable Securities owned by such Holder as of the date hereof, proposes to file on behalf of any of its security holders a registration statement (or post-effective amendment to a prior registration statement) under the Securities Act on any form (other than a registration statement on Form S-4 or S-8 or any successor form for securities to be offered in a transaction of the type referred to in Rule 145 under the Securities Act or to employees of the Company pursuant to any employee benefit plan, respectively) for the registration of securities for resale by certain selling stockholders, it will give written notice to all Holders at least 20 days before the initial filing with the SEC of such registration statement (or post-effective amendment). The notice will offer to include in such filing (or, if applicable, pursuant to Rule 429(b) under the Securities Act, a new registration statement with a combined prospectus that serves as a post-effective amendment to a prior registration statement) the aggregate number of shares of Registrable Securities as the Holders may request.

Each Holder desiring to have Registrable Securities registered under this Section 1.2 shall advise the Company in writing, within 10 days after the date of receipt of such notice, setting forth the amount of such Registrable Securities for which registration is requested. The Company shall include in such filing the number of shares of Registrable Securities for which registration is so requested and shall use its reasonable best efforts to effect registration under the Securities Act of such shares. Except as otherwise provided in Section 1.4, the Company shall bear all expenses of such registration.

1.3               Registration Procedures . If the Company is required by the provisions of Section 1.2 to use its reasonable best efforts to effect the registration of any of its securities under the Securities Act, the Company will, as expeditiously as possible:

(a)                 prepare and file with the SEC a registration statement with respect to such securities, and any amendments and supplements thereto, and use its reasonable best efforts to keep the registration statement continuously effective for as long as any Holder holds Registrable Securities;

(b)                furnish to each Holder such number of copies of a prospectus or prospectus supplement in conformity with the requirements of the Securities Act;

(c)                 use its reasonable efforts to register or qualify the securities covered by such registration statement under such other securities or blue sky laws of such jurisdictions within the United States as each Holder reasonably requests ( provided , however , that the Company will not be obligated to qualify to do business in any jurisdiction in which it is not then qualified or to file any general consent to service or process); and

(d)                promptly notify each Holder whose Registrable Securities are intended to be, or are, covered by such registration statement (i) when a prospectus or any prospectus supplement or post-effective amendment has been filed and, with respect to a registration statement or any post-effective amendment, when the same has become effective; (ii) of the happening of any event that makes any statement made in a registration statement or related prospectus untrue or that requires the making of any changes in such registration statement or prospectus, or other documents, so that they will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading; or (iii) the temporary suspension of effectiveness of such registration statement as permitted by Section 1.6(b).

The Company will have no obligation to take any action pursuant to this Agreement in respect of the securities that are to be registered at the request of any Holder unless such Holder furnishes to the Company such information regarding the securities held by such Holder and the intended method of disposition of the securities as the Company reasonably requests and as required in connection with the action taken by the Company.

Each Holder agrees that, upon receipt of any notice from the Company of the happening of any event of the kind described in Sections 1.3(e)(ii) or (iii), such Holder shall immediately discontinue such Holder’s disposition of Registrable Securities pursuant to the registration statement relating to such Registrable Securities until such Holder’s receipt of the copies of a supplemented or amended prospectus or receipt of notice that the suspension has been lifted, as applicable.

1.4               Expenses . The Company shall pay all expenses it incurs in complying with this Agreement, including, without limitation, all registration and filing fees, printing expenses, fees and disbursements of counsel for the Company, expenses of any special audits incident to or required by any such registration and expenses of complying with the securities or blue sky laws of any jurisdiction pursuant to Section 1.3(c), except that the Company will not be liable for any fees and expenses incurred by the Holders, including, but not limited to, fees and expenses of counsel for the selling security holders or brokerage fees or underwriting discounts or commissions, if any.

1.5               Indemnification and Contribution.

(a)                 In the event of any registration of any Registrable Securities under the Securities Act pursuant to this Agreement, the Company shall indemnify and hold harmless to the fullest extent permitted by law the Holder of such Registrable Securities, such Holder’s directors and officers, and each other person who participated in the offering of such Registrable Securities and each other person, if any, who controls such Holder or such participating person within the meaning of the Securities Act, against any losses, claims, damages or liabilities, joint or several, to which such Holder or any such director or officer or participating person or controlling person may become subject under the Securities Act or any other statute or at common law, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon (i) any alleged untrue statement of any material fact contained, on the effective date thereof, in any registration statement under which such securities were registered under the Securities Act, any preliminary prospectus or final prospectus contained therein, or any amendment or supplement thereto, or (ii) any alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, and shall reimburse such Holder or such director, officer or participating person or controlling person for any legal or any other expenses reasonably incurred by such Holder or such director, officer or participating person or controlling person in connection with investigating or defending any such loss, claim, damage, liability or action;  provided however , that the Company will not be liable in any such case to the extent that any such loss, claim, damage or liability arises out of or is based upon any actual or alleged untrue statement or actual or alleged omission made in such registration statement, preliminary prospectus, prospectus or amendment or supplement in reliance upon and in conformity with written information furnished to the Company by such Holder specifically for use therein. Such indemnity will remain in full force and effect regardless of any investigation made by or on behalf of such Holder or such director, officer or participating person or controlling person, and will survive the transfer of such securities by such Holder.

(b)                Each Holder, by acceptance hereof, agrees to indemnify and hold harmless to the fullest extent permitted by law the Company, its directors and officers and each other person, if any, who controls the Company within the meaning of the Securities Act against any losses, claims, damages or liabilities, joint or several, to which the Company or any such director or officer or any such person may become subject under the Securities Act or any other statute or at common law, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon information provided in writing to the Company by such Holder specifically for use in the following documents and contained, on the effective date thereof, in any registration statement under which securities were registered under the Securities Act at the request of such Holder, any preliminary prospectus or final prospectus contained therein, or any amendment or supplement thereto. Notwithstanding the provisions of this paragraph (b) or paragraph (d) below, no Holder will be required to indemnify any person pursuant to this Section 1.5 or to contribute pursuant to paragraph (d) below in an amount in excess of the amount of the aggregate net proceeds received by such Holder in connection with any such registration under the Securities Act.

(c)                 Any person entitled to indemnification hereunder will (i) give prompt written notice to the indemnifying party of any claim with respect to which it seeks indemnification (although the failure to give such notice will not limit the rights of such person, except to the extent the indemnifying party is actually prejudiced thereby) and (ii) unless in such indemnified party’s reasonable judgment a conflict of interest between such indemnified and indemnifying parties may exist with respect to such claim, permit such indemnifying party to assume the defense of such claim with counsel reasonably satisfactory to the indemnified party;  provided however , that any person entitled to indemnification hereunder will have the right to employ separate counsel and to participate in the defense of such claim, but the fees and expenses of such counsel will be at the expense of such person unless (A) the indemnifying party has agreed to pay such fees or expenses or (B) the indemnifying party shall have failed to assume the defense of such claim and employ counsel reasonably satisfactory to such person. If such defense is not assumed by the indemnifying party as permitted hereunder, the indemnifying party will not be subject to any liability for any settlement made by the indemnified party without its consent (but such consent will not be unreasonably withheld or delayed). If such defense is assumed by the indemnifying party pursuant to the provisions hereof, such indemnifying party may not settle or otherwise compromise the applicable claim unless (i) such settlement or compromise contains a full and unconditional release of the indemnified party or (ii) the indemnified party otherwise consents in writing, which consent may not be unreasonably withheld or delayed. An indemnifying party who is not entitled to, or elects not to, assume the defense of a claim will not be obligated to pay the fees and expenses of more than one counsel for all parties indemnified by such indemnifying party with respect to such claim, unless in the reasonable judgment of any indemnified party, a conflict of interest may exist between such indemnified party and any other of such indemnified parties with respect to such claim, in which event the indemnifying party will be obligated to pay the reasonable fees and disbursements of such additional counsel or counsels.

(d)                If the indemnification provided for in this Section 1.5 from the indemnifying party is unavailable to an indemnified party hereunder in respect of any losses, claims, damages, liabilities or expenses referred to therein, then the indemnifying party, in lieu of indemnifying such indemnified party, shall contribute to the amount paid or payable by such indemnified party as a result of such losses, claims, damages, liabilities or expenses in such proportion as is appropriate to reflect the relative fault of the indemnifying party and indemnified parties in connection with the actions which resulted in such losses, claims, damages, liabilities or expenses, as well as any other relevant equitable considerations. The relative fault of such indemnifying party and indemnified parties will be determined by reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact, has been made by, or relates to information supplied by, such indemnifying party or indemnified parties, and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such action. The amount paid or payable by a party as a result of the losses, claims, damages, liabilities and expenses referred to above will be deemed to include any legal or other fees or expenses reasonably incurred by such party in connection with any investigation or proceeding. The parties agree that it would not be just and equitable if contribution pursuant to this Section 1.5(d) were determined by  pro - rata  allocation or by any other method of allocation which does not take account of the equitable considerations referred to in the immediately preceding paragraph. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.

1.6               Certain Limitations on Registration Rights . Notwithstanding the other provisions of this Agreement:

(a)                 The Company will not be obligated to register the Registrable Securities of any Holder if, in the opinion of counsel to the Company, the sale or other disposition of such Holder’s Registrable Securities, in the manner proposed by such Holder, may be effected without registering such Registrable Securities under the Securities Act.

(b)                The Company will have the right to delay the filing or delay or suspend the effectiveness of a registration statement contemplated by this Agreement during one or more periods aggregating not more than 90 days in any twelve-month period in the event that (i) the Company would, in accordance with the advice of its counsel, be required to disclose in the prospectus information not otherwise then required by law to be publicly disclosed and (ii) in the judgment of the Company’s board of directors, there is a reasonable likelihood that such disclosure, or any other action to be taken in connection with the prospectus, would materially and adversely affect any existing or prospective material business situation, transaction or negotiation or otherwise materially and adversely affect the Company.

SECTION 2.     Board Rights.

2.1               Appointment of Designee . If, by December 31, 2015, Purchaser has purchased from the Company an aggregate of $2,000,000 in the Company’s equity securities (inclusive of the Subscription Shares, but exclusive of any Warrant Shares or shares issuable upon exercise of any subsequently issued warrants) in accordance with a mutually agreeable timetable for additional investments (but subject to Section 2.3), then by no later than January 31, 2016, the Company shall expand its board of directors (the “ Board ”) by one director and appoint a designee of Purchaser reasonably acceptable to the Board (a “ Designee ”) to fill the vacancy.

2.2               Nomination at Subsequent Annual Meetings . If a Designee is appointed to the Board pursuant to Section 2.1, then for so long as the Purchaser or any of its affiliates own more than 50% of the shares of Common Stock held by them as of December 31, 2015, and subject to satisfaction of all legal and governance requirements applicable to all Board members regarding service as a director of the Company, the Company shall cause the nomination of the Designee (or an alternative designee of the Purchaser who is reasonably acceptable to the Board, such alternative to be deemed the Designee for purposes of this Section 2 upon election or appointment) for election to the Board at each subsequent annual meeting, or upon the death, resignation, removal or disqualification of the Designee, if earlier. The Purchaser and/or the Designee shall provide written notice of the Designee to the Company, together with any information pertaining to the Designee reasonably requested by the Company, including a duly completed directors’ and officers’ questionnaire typically furnished to the Board by its directors.

2.3               Limitation on Board Rights . Notwithstanding anything to the contrary in this Section 2, the Company shall not be obligated to offer or sell any shares of Common Stock to the Purchaser other than the Subscription Shares (and the Warrant Shares upon exercise of the Warrants) and shall have no liability to the Purchaser for such refusal to offer or sell shares, even if such refusal prevents Purchaser from satisfying the ownership conditions set forth in Section 2.1. However, should Purchaser invest at least an aggregate of $1,500,000 in the Company’s equity securities, Purchaser shall have the right to request the Board to consider the appointment of the Designee to the Board.

SECTION 3.     Miscellaneous.

3.1               Notices.

(a)                 Each party giving or making any notice, request, demand or other communication (each, a “ Notice ”) pursuant to this Agreement shall give the Notice in writing and use one of the following methods of delivery, each of which for purposes of this Agreement is a writing: personal delivery, Registered or Certified Mail (in each case, return receipt requested and postage prepaid), nationally recognized overnight courier (with all fees prepaid; signature upon receipt), facsimile or e-mail.

(b)                Any party giving a Notice shall address the Notice to the appropriate person at the receiving party (the “ Addressee ”) at the last-known address appearing on the books of the Company maintained for such purpose, if to a Holder, and to the Company’s corporate headquarters, attention: Chief Executive Officer, if to the Company, or, in each case, to another Addressee or another address as designated by a party in a Notice pursuant to this Section.

(c)                 Except as provided elsewhere in this Agreement, a Notice is effective only if the party giving the Notice has complied with subsections (a) and (b) of this Section 3.1 and if the Addressee has received the Notice. Notice is deemed to have been received upon date of the return receipt or signature upon receipt, or confirmation of receipt via facsimile or e-mail, as appropriate.

3.2               No Assignment by Holders . Except as expressly provided in this Section 3.2, no Holder may assign any of its rights or delegate any of its obligations under this Agreement without the prior written consent of the Company and any such purported assignment will be null and void. A Holder may assign its rights under this Agreement without such consent to any affiliate of such Holder who acquires Registrable Securities from such Holder or its affiliates; provided however , that any such affiliate must agree to agree to be bound by the terms of this Agreement , and become a Holder for purposes of this Agreement. Nothing in this Agreement will be construed to give any third party any legal or equitable right, remedy or claim under or with respect to this Subscription Agreement, except such rights as may inure to a permitted assignee pursuant to this Section 3.2.

3.3               Governing Law; Jurisdiction; Jury Waiver . This Agreement is governed by, construed and enforced in accordance with the laws of the State of New York without giving effect to the conflict of laws provisions thereof. Each of the parties hereby submits to personal jurisdiction and waives any objection as to venue in the County of New York, State of New York. Service of process on the parties in any action arising out of or relating to this Agreement will be effective if mailed to the parties in accordance with Section 3.1. The parties waive all right to trial by jury in any action or proceeding to enforce or defend any rights hereunder.

3.4               Severability . If any provision of this Agreement is determined to be invalid, illegal or unenforceable, the remaining provisions of this Agreement remain in full force, if the essential terms and conditions of this Agreement for each party remain valid, binding, and enforceable.

3.5               Entire Agreement . This Agreement represents the complete agreement and understanding of the parties hereto in respect of the subject matter contained herein and therein. This Agreement supersedes all prior agreements and understandings between the parties with respect to the subject matter hereof.

3.6               Counterparts . This Agreement may be executed in any number of counterparts and by the parties hereto in separate counterparts (including by .pdf or facsimile), each of which when so executed will be deemed to be an original and all of which taken together will constitute one and the same agreement.

3.7               Termination . The Company’s obligations under this Agreement will cease with respect to any person when such person ceases to be a Holder. Notwithstanding the foregoing, the Company’s obligations under Sections 1.4 and 1.5 will survive in accordance with their terms.

[signature page to follow]

 
 

This Registration Rights Agreement is being signed effective as of the date first written above.

GUIDED THERAPEUTICS, INC.

 

 

 

By:____________________________________

Name: Gene S. Cartwright

Title: Chief Executive Officer

 

ITEM MEDIKAL TEKNOLOJILERI LTD STI

 

 

By:____________________________________

Name: Muzaffer Yazici

Title: Managing Director

 

Exhibit 99.1

  

 
 
  5835 Peachtree Corners East, Suite D
  Norcross, GA 30092

   

FOR IMMEDIATE RELEASE

 

Guided Therapeutics Announces Initial $200,000 Investment from Turkish

Distributor, ITEM Medical Technologies Group

 

NORCROSS, GA and ANKARA, TURKEY (September 8, 2014) – Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that its Turkish distributor, ITEM Medical Technologies Group, referred to as ITEM, has committed to invest $200,000 in a private placement of Guided Therapeutics’ common stock.

 

Pursuant to the private placement, the Company will issue ITEM 651,042 shares of common stock priced at $0.3072 per share and a warrant to purchase an additional 325,521 shares. The warrants will have at issuance a five-year term, an exercise price per share of $0.4608, and be subject to a mandatory exercise provision should the average trading price of the Company’s common stock over any 30 consecutive day trading period exceed $0.9216. The Company expects to use the net proceeds from the private placement for efforts to achieve FDA approval for the Guided Therapeutics LuViva® Advanced Cervical Scan, to increase manufacturing and international sales of LuViva, to enhance the Company’s intellectual property portfolio, and other related corporate purposes.

 

Should ITEM’s total investment reach $2.0 million by the end of 2015, ITEM will receive the right to have a designee appointed to the Company’s board of directors, and nominated by the board for reelection at subsequent annual meetings.

 

The securities to be issued to ITEM have not been registered under the Securities Act of 1933, as amended, and none of these securities may be offered or sold in the United States other than in accordance with Regulation S under the Securities Act, pursuant to registration under the Securities Act, or pursuant to an applicable exemption from registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any jurisdiction where such offer, solicitation or jurisdiction would be unlawful.

 

Forward-Looking Statements Disclaimer: A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments, including among others, the timing of the closing of the private placement and the amount of gross proceeds and the use of net proceeds from the private placement. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics’ actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include those related to our ability to complete the transactions contemplated by the private placement, our ability to realize the expected benefits of the private placement, the sufficiency of the capital raised in the private placement and the ability of Guided Therapeutics to raise additional capital, the extent of dilution of the holdings of our current stockholders upon conversion or exercise of securities issued in connection with capital raising efforts, the early stage of Guided Therapeutics products in development, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the uncertainty of capital to develop products or continue as a going concern, the uncertainty of regulatory approval of products, dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading “Risk Factors” in Guided Therapeutics’ reports filed with the Securities and Exchange Commission, including Guided Therapeutics’ Annual Report on Form 10-K for the fiscal year ended December 31, 2013, and subsequent quarterly reports.

# # #

Contacts

Bill Wells, Guided Therapeutics – 770-242-8723

Investors: Alison Ziegler, Cameron Associates – 212-554-5469